Heart and Kidney Scale Balancing Inotropes

Inotropes in Acute Heart Failure: Are All Created Equal?

Author's portrait.
Lena Voss in Health & Wellness December 2025 • 4 min read.

"A new study sheds light on the impact of different inotropes on kidney function in acute heart failure patients."


Heart failure (HF) poses a significant global health challenge due to its high prevalence, morbidity, and mortality rates. Experts predict a further increase in HF prevalence by 25% by 2030, underscoring the urgency for effective management strategies.

Acute HF is a leading cause of hospitalization among individuals over 65 in developed countries. This life-threatening condition requires prompt evaluation and treatment. In Portugal, HF has the highest in-hospital mortality rate among all cerebro-cardiovascular diseases.

HF can lead to dysfunction in various organs, particularly the kidneys, leading to cardiorenal syndrome (CRS). CRS describes the concurrent worsening of both cardiac and renal function. This syndrome carries a poor prognosis, associated with longer hospital stays, increased mortality, and higher readmission rates.

Dobutamine vs. Levosimendan: Impact on Cardiorenal Syndrome

Heart and Kidney Scale Balancing Inotropes

The treatment of acute HF with inotropes remains a controversial topic due to uncertainties surrounding their use. While inotropes can improve hemodynamic parameters, they also increase myocardial oxygen demand, promote arrhythmias, and interact with pro-apoptotic mechanisms. Given the clinical implications of CRS, researchers have investigated the potential effects of inotropes on renal function.

Inotropes like dobutamine and levosimendan can improve cardiac output and, consequently, renal perfusion. Levosimendan also exhibits vasodilatory effects on renal arteries and veins, suggesting a potential renoprotective effect.

  • A retrospective study evaluated the incidence of CRS based on the type of inotrope used (levosimendan vs. dobutamine).
  • The study included 108 consecutive patients admitted for acute HF requiring inotropic support.
  • The incidence of CRS was significantly higher in the dobutamine group compared to the levosimendan group (77% vs. 49%, p < 0.01).
  • Cystatin C was identified as the only independent predictor of CRS occurrence.
  • In-hospital mortality was also higher in the dobutamine group (42% vs. 9%, p < 0.01).
  • The presence of CRS and the type of inotrope used were independent predictors of in-hospital mortality.
  • Renal function recovery at discharge tended to be partial in the dobutamine group compared to the levosimendan group.
The study suggests levosimendan might be more beneficial in acute HF patients with renal repercussions. However, the retrospective nature and heterogeneity of the study population limit the ability to draw firm conclusions about the superiority of one inotrope over another. Patients in the dobutamine group may have had a higher baseline risk profile, potentially influencing the outcomes.

The Road Ahead: Optimizing Inotropic Therapy in Acute Heart Failure

This research contributes valuable insights into the management of acute HF, particularly concerning the impact of inotropes on renal function. Given the limited data in this area, the study provides a real-world perspective on the use of inotropes in patients with acute HF.

While levosimendan appears promising for managing acute HF with renal involvement, further research is needed to explore the differentiating characteristics and potential benefits of various inotropes for treating acute HF.

Future studies should focus on robustly investigating the distinct characteristics and potential benefits of different inotropes available for treating acute HF, especially in the context of cardiorenal syndrome. Ultimately, understanding these nuances will help clinicians optimize treatment strategies and improve outcomes for this vulnerable patient population.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1016/j.repc.2017.07.002, Alternate LINK

Title: Inotrópicos Na Abordagem Da Insuficiência Cardíaca Aguda E Sua Repercussão Renal – Serão Todos Iguais?

Subject: Cardiology and Cardiovascular Medicine

Journal: Revista Portuguesa de Cardiologia

Publisher: Elsevier BV

Authors: Inês Rangel

Published: 2017-09-01

Everything You Need To Know

1

What are inotropes, and how are they used in treating heart failure?

Inotropes are medications used to improve the heart's ability to pump blood more effectively in patients experiencing acute heart failure (HF). They work by increasing the force of heart muscle contractions, thus improving cardiac output. The use of inotropes is a common strategy when managing acute HF.

2

What is cardiorenal syndrome (CRS), and why is it important in the context of acute heart failure?

Cardiorenal Syndrome (CRS) is a condition where both heart and kidney function worsen simultaneously. This is a critical consideration in acute HF, as it significantly impacts patient outcomes. The study highlights that the incidence of CRS was considerably higher in patients treated with Dobutamine compared to Levosimendan, and CRS was independently associated with higher in-hospital mortality.

3

What inotropes were compared, and what were the key findings regarding their impact on patients?

The study compared two specific inotropes: Dobutamine and Levosimendan. Dobutamine is a frequently used inotrope that can improve heart function. Levosimendan, on the other hand, has vasodilatory effects, potentially protecting the kidneys. The research indicated that patients treated with Levosimendan had a lower incidence of CRS and better renal function recovery compared to those treated with Dobutamine.

4

Why is it important to understand the effect of inotropes on kidney function in acute heart failure?

The implications of the study are significant because they address the impact of different inotropes on kidney function. The research suggests that the choice of inotrope may affect the risk of developing CRS, which is associated with increased mortality, prolonged hospital stays, and higher readmission rates. These findings underscore the need for careful consideration when selecting inotropic agents for acute HF patients, especially those with potential renal complications.

5

What do the study's findings suggest about the choice of inotropes for patients with acute heart failure and kidney issues?

The study's findings suggest that Levosimendan might be more beneficial in acute HF patients with renal repercussions due to its potential renoprotective effects. However, the retrospective study design and the heterogeneity of the patient population mean that drawing firm conclusions about the superiority of one inotrope over another is limited. Further research is required to confirm these findings and develop more effective treatment strategies for acute HF.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.